Gala Health Tirzepatide Review: Cost, Compounded vs Brand & Honest Verdict (2026)

Gala Health pairs a low compounded headline price with a footprint most of its rivals cannot match — but the headline carries a condition that changes the arithmetic. Gala advertises compounded tirzepatide from $179/month, and that rate is calculated on a yearly subscription: the storefront prints "All doses included. Yearly subscription." directly beneath the figure. No month-to-month price is published anywhere on the site. The cheapest term Gala quotes in prose is $199/month on a 3-month plan. What is not conditional is the reach — availability in all 50 states — plus a brand-name pathway if you specifically want an FDA-approved product. This review covers what Gala is, what it dispenses, the compounded-versus-brand distinction, what its pricing actually commits you to, and the catches. Some of the providers we cover are affiliate partners: we earn a commission if you start care through our links, at no extra cost to you — see our disclosure. Every fact here comes from the company's own published program.

What Gala Health is

Gala Health (operated by AI Coaching Inc, with care delivered through OpenLoop-affiliated medical groups) is a telehealth weight program pitched specifically at women — its product pages read "for Women" and describe dosing "for women's bodies" — and it sells HRT and menopause care alongside GLP-1. A licensed prescriber reviews an online intake and, where appropriate, compounded tirzepatide ships from $179/month on a yearly subscription, with a $149/month microdose tier on that same yearly term and a 3-month plan quoted at $199/month. Everything is injection only; there is no oral or sublingual pathway. Unusually for a compounded provider at this price, Gala says it is available in all 50 states, though it publishes no state list to check that against. It is LegitScript-certified, and its prices are posted publicly rather than hidden behind a quiz — a real point in its favour. Less transparent: the dispensing pharmacy is never named (only "a wide network"), and no individual clinician is named — the site shows "trained at" logos for Mount Sinai, Harvard and Columbia rather than the people who will actually treat you.

The compounded-vs-brand question

Two very different products share the name tirzepatide:

• •Brand tirzepatide is Eli Lilly's FDA-approved Zepbound (weight management, obstructive sleep apnea) and Mounjaro (type 2 diabetes) — the exact molecule and dose studied in the pivotal trials.
• •Compounded tirzepatide is pharmacy-made, not FDA-approved, and was not the product tested in those trials.

Gala's headline $179/month tirzepatide is compounded — and billed as a yearly subscription — which is why it sits far below brand pricing. That matters more in 2026: the FDA declared the tirzepatide shortage resolved in October 2024, and the enforcement discretion that permitted routine large-scale compounding ended in early 2025 (around February 18, 2025 for 503A pharmacies, March 19, 2025 for 503B outsourcing facilities) — the full timeline is in our guide to whether compounded tirzepatide is still legal in 2026. Note that Gala's brand-name pathway is for Ozempic (semaglutide), a different molecule from tirzepatide, and it is priced very high (see below), so it is not a cheap route to the brand tirzepatide drug.

What Gala Health costs in 2026

Gala's published prices are low, and every one of them carries a term:

• •Compounded tirzepatide — $179/month, billed as a yearly subscription, all doses included, so titrating up costs nothing extra. This is the headline figure, and "Yearly subscription" is printed directly under it.
• •Microdose tier — $149/month, also yearly. Lower-than-standard dosing by design, so it is not a cheaper route to a therapeutic tirzepatide dose.
• •3-month plan — $199/month. The shortest commitment Gala quotes anywhere, and the number to use if you are not prepared to pay for a year.
• •Brand Ozempic — from $1,299/month. Semaglutide, a different molecule, so it is best understood as an add-on for patients who specifically want brand semaglutide rather than a competitive tirzepatide route.

No month-to-month rate is published anywhere on the site. That is the most important thing to know about Gala's pricing: $179 is not what it costs to try the service for a month, it is what a year costs divided by twelve. The genuinely unconditional advantage here is the all-50-state coverage, which most compounded-only startups cannot match.

For context on the brand tirzepatide drug, LillyDirect sells brand Zepbound self-pay vials at roughly $299–$449/month depending on dose (prices effective February 23, 2026; 28-day supply) — and that is a true month-to-month price with nothing to prepay. Setting Gala's $179 against it is not like-for-like: one is a rate you can stop paying next month, the other is a year bought up front. The honest comparison is Gala's $199/month 3-month plan against LillyDirect's $299 floor — still cheaper, but by roughly $100/month rather than the $120–$270 the headline implies, still a commitment, and still a non-FDA-approved product measured against the approved one. If you do commit to Gala's year, the arithmetic is about $2,148 for twelve months of compounded tirzepatide versus roughly $3,588 for twelve month-to-month months of brand Zepbound at its cheapest dose — a real saving, but one you pay for before you know how you tolerate the drug. For the full cash-price picture, see our Zepbound cost and savings guide.

How the care model holds up

Gala's strengths are real, but they need stating precisely: a low compounded rate at $179/month if you buy a year (or $199/month on three), all-50-state availability that is rare at this price, a brand pathway for patients who want one, publicly posted prices, LegitScript certification, and adjacent HRT/menopause care. The trade-offs: no month-to-month price is published anywhere on the site, so the advertised rate is not available on a try-it basis; the tirzepatide is compounded and not FDA-approved; the dispensing pharmacy is never named and no treating clinician is named; the all-50-state claim comes with no published state list; the brand Ozempic option is very expensive at $1,299 and is a different molecule; there is no oral or sublingual pathway; and Gala is a newer operator with a shorter track record than established platforms. As with any GLP-1 service — and especially one that asks for a year up front — confirm continuity of care and read the cancellation terms before you pay; tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Separate the provider from the medication, and the brand molecule from a compounded copy. Brand tirzepatide's efficacy is trial-grade: in the 72-week SURMOUNT-1 trial, adults without diabetes lost on average roughly 15% to 21% of body weight across the 5–15 mg doses, versus about 3% on placebo¹; against semaglutide in SURMOUNT-5, tirzepatide produced significantly greater weight loss — about 20% versus 14%². Those results were established with the brand molecule; compounded versions were never tested in those trials. Note too that a microdose tier uses lower-than-standard doses, so it should not be expected to match full-dose trial results. The full picture is in our tirzepatide evidence guide and our look at tirzepatide microdosing.

The honest verdict

Gala Health suits a specific buyer: someone who has already settled on compounded tirzepatide, wants it in a state most compounded-only startups do not reach, and is willing to pay for a year up front. That last clause is the whole verdict. At $179/month Gala reads like one of the cheapest programs on our index, but that rate is a yearly subscription, and the shortest term it publishes — $199/month on three months — is an ordinary price rather than a standout one. Measured against a true month-to-month benchmark, the value case is good rather than exceptional.

What survives the correction is the coverage and the brand pathway: all 50 states is a genuine differentiator, and keeping an FDA-approved option on the menu — albeit Ozempic, a different molecule, at $1,299 — is more than most compounded sellers offer. The reservations are the year-long commitment behind the headline rate, the unnamed pharmacy and unnamed clinicians, the missing state list, the shorter track record, and the lack of an oral pathway. If you want a flat price with included nurse/dietitian support, weigh CoreAge Rx; if you specifically want brand tirzepatide, price it against LillyDirect. See our best tirzepatide providers ranking and best place to get Zepbound online roundup.